Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System [PDF]
ChildrenBackground/Objectives: Infliximab biosimilars entered the United States (US) market in November 2016. Uptake of infliximab biosimilars has been slow in adult studies.
Ross M. Maltz +2 more
doaj +2 more sources
Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab. [PDF]
PLoS ONE, 2015 ObjectiveIn patients with postoperative recurrence of Crohn's disease endoscopic and clinical remission can be maintained for up to 1 year with low infliximab doses (3 mg/Kg).
Dario Sorrentino +4 more
doaj +4 more sources
Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study [PDF]
Gut and LiverBackground/Aims: Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab trough level. An understanding of pharmacokinetics (PKs) is important to maintain an optimal trough level.
Joo Hye Song +7 more
doaj +2 more sources
Prediction of deep remission through serum TNF-α level at 1 year of treatment in pediatric Crohn’s disease [PDF]
Scientific ReportsA pilot study investigated the cytokine profile (IL-6, TNF-α, IL-17 A, and IL-10) at diagnosis, affecting infliximab (IFX) trough levels (TLs) in pediatric patients with Crohn’s disease (CD).
Seon Young Kim +6 more
doaj +2 more sources
Gut and Liver, 2023 Background/Aims: The clinical efficacy and safety of CT-P13 are comparable to originator infliximab for Crohn’s disease in CT-P13 3.4 study (NCT02096861).
Jihye Park +9 more
doaj +1 more source
BMC Gastroenterology, 2022 Background Recent studies have confirmed that combined surgery and anti-TNF therapy could improve outcomes in patients with perianal fistulising Crohn’s disease (PFCD).
Ping Zhu +6 more
doaj +1 more source
Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease. [PDF]
PLoS ONE, 2018 Overt fibrostenotic disease is a relative contraindication for anti-TNF therapy in Crohn's disease. We hypothesized that subclinical fibrosis may also contribute to an incomplete response to anti-TNF therapy before the onset of symptomatic stenosis.In a ...
Jessica R de Bruyn +10 more
doaj +1 more source
Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices. [PDF]
, 2020 ObjectiveIt is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Bansback, Nick +8 more
core +1 more source
Infliximab‐induced seizures in a patient with Crohn’s disease: a case report
BMC Gastroenterology, 2021 Background Infliximab-induced seizures in patients with Crohn’s disease are extremely rare and the mechanism of infliximab-induced seizures is unclear.
Zhijie Lv, Xiaoqi Zhang, Li Wu
doaj +1 more source
Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
GMS Ophthalmology Cases, 2023 Objective: To present a case with infliximab-induced retrobulbar optic neuritis.Case description: A 58-year-old woman presented to our clinic with a two-day history of blurred vision in her right eye.
Dündar, Sema +4 more
doaj +1 more source